News archive

'Encouraging' uptake in HPV vaccination trial

TUESDAY 29 APRIL 2008

Around seven in ten girls will be vaccinated against the human papillomavirus (HPV) when it is introduced in the autumn, a new study suggests.

A pilot study led by researchers from the University of Manchester saw two primary care trusts deliver the HPV vaccine to secondary schools in their surrounding areas.

The parents of 2,817 girls aged between 12 and 13 had the opportunity to take part in the trial as part of an effort to predict take-up for the forthcoming national immunisation programme and assess how easy it is to administer the vaccine to adolescent girls.

Results of the study show that 70.6 per cent of the eligible girls received the first vaccine and 68.5 per cent the second.

Three doses are needed - an initial jab and then boosters after one and six months for the vaccination, which prevents two types of HPV linked with 70 per cent of cervical cancers, to be effective.

"These are encouraging results for the forthcoming national HPV vaccine programme but the final criterion for success will be the proportion of girls who receive all three vaccine doses," the researchers conclude.

Of the parents who refused to allow their daughters to receive the vaccination, 36 per cent said they had been influenced by a lack of available information and doubts over its long-term safety, ten per cent were worried that the girls were too young and three per cent thought the vaccine could have a bearing on future sexual behaviour - as HPV is transmitted sexually, there are concerns the vaccine could encourage promiscuity.

Researchers also found that delivery of the vaccine posed some problems, largely as a result of the fact that it was administered at the start of the academic year, when schools are particularly busy.

In addition, 16.3 per cent of girls missed their first appointment and 23.6 per cent their second - leading to scheduling difficulties.

Dr Jo Waller, a health psychologist with Cancer Research UK, commented: "This study provides encouraging evidence that it is possible to achieve acceptable uptake of the first two doses of the HPV vaccine in a school-based programme. But it highlights the logistical challenges of delivering a three dose vaccine to girls, some of whom may not be at school for the scheduled immunisation sessions."

She added: "It also suggests that a significant minority of parents may not provide consent for their daughters to be vaccinated. The reasons for this need further investigation."

The study appears in the British Medical Journal Online.

News provided by Adfero in collaboration with Cancer Research UK. Please note that all copy is © Adfero Ltd and does not reflect the views or opinions of Cancer Research UK unless explicitly stated.


* Exercise reduces the risk of breast cancer in most women
* Scientists identify genetic changes involved in childhood cancer
* Mathematical model predicts breast tumours grow faster in younger women
* Smoking death risks significantly reduced within five years of quitting
* Researchers suggest playgroups could be linked to lower leukaemia risk
* Healthy habits linked to higher quality of life among cancer survivors
* Study demonstrates drug's effect on breast cancer stem cells
* Mums unaware of breastfeeding benefits
* 'Encouraging' uptake in HPV vaccination trial
* Benefits 'far outweigh' reported side-effects of chemotherapy drug
A - Z index A - Z index
Contact us Contact us
Donate now Donate now
Glossary Glossary
Print this page Print this page
AddThis Feed Button

Find out more
 
 
About this site   Accessibility   Donate now   Privacy   Site Map   Terms & Conditions   Top of page

Cancer Research UK is a registered charity No. 1089464.
Registered as a company limited by guarantee in England & Wales No. 4325234.
Registered address 61 Lincoln's Inn Fields, London, WC2A 3PX.